https://doi.org/10.55788/288a2387
Younger adults are relatively more frequently diagnosed with stage IV lung cancer than older adults, as was demonstrated by an American cohort study. Therefore, it is necessary to develop strategies that improve the early detection in younger patients who are ineligible for lung cancer screening [1].
Dr Alexandra Potter (Massachusetts General Hospital, MA, USA) and colleagues investigated the differences in lung cancer staging at diagnosis and overall survival (OS) times between younger and older adults since the introduction of lung cancer screening. For this purpose, the investigators used the SEER and US National Cancer Database to analyse all patients from 20 to 79 years old who were diagnosed with non-small cell lung cancer between 2010 and 2018. Patients were categorised into 10-year age intervals. In total, 1,328 patients were in the youngest age group (20–29 years) and 447,366 patients were in the oldest age group (70–79 years).
Carcinoid tumours were more frequently observed in younger patients (20–29: 58%; 30–39: 29%) than in older patients (70–79: 4%; P<0.001). Importantly, younger patients were relatively more likely to be diagnosed with stage IV lung cancer (20–29: 76%; 30–39: 70%) than older patients (60-69: 45%; 70-79: 40%). Since 2010, the rate of stage I versus stage IV diagnosing is developing favourably in the older age groups, likely due to lung cancer screening; a status quo is observed in younger patients. Dr Potter thus stated that strategies to increase the early detection of lung cancer in younger patients are urgently needed.
Additional findings included that in the younger age groups, patients were relatively more likely to be Black or Asian than White, compared with the older age groups (P<0.001). The 5-year OS rate was similar at 20% in patients ages 20–29 years, 27–28% in patients aged 30-69 years, and 24% in those aged 70–79 years.
- Potter AL, et al. Early diagnosis of lung cancer among younger vs older adults: widening disparities in the era of lung cancer screening. OA05.06, WCLC 2022, Vienna, Austria, 06–09 August.
Copyright ©2022 Medicom Medical Publishers
Posted on
« Intensive co-located smoking cessation programme highly effective during lung screening Next Article
Pembrolizumab plus lenvatinib performs well in MPM »
Table of Contents: WCLC 2022
Featured articles
IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC
Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?
WCLC 2022 Congress Round-Up
Sugemalimab offers PFS benefits for unresectable NSCLC
First results of sotorasib plus pembrolizumab in KRAS p.G12C-mutated NSCLC
IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC
Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?
NADIM: Risk of progression identified through RNA sequencing
NADIM II: OS benefit of neoadjuvant nivolumab plus chemotherapy in NSCLC
POSEIDON: Novel option for harder-to-treat subgroups of patients with metastatic NSCLC?
First DLL3-targeted therapy shows promise in SCLC
KEYNOTE-604: Very durable responses on pembrolizumab plus EP in SCLC
Talazoparib plus temozolomide appears efficacious in ES-SCLC
Pembrolizumab plus lenvatinib performs well in MPM
Early detection strategies in younger patients with lung cancer are urgently needed
Intensive co-located smoking cessation programme highly effective during lung screening
Do we underestimate the effect of air pollution on lung cancer incidence?
Interventions needed to address sexual health in lung cancer
Related Articles

‘Prehab’ may make surgery possible for more lung cancer patients
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy